AbbVie Inc. (ABBV) – Financial and Strategic SWOT Analysis Review

AbbVie Inc. (ABBV) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $300

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
64
Pharmaceuticals and Healthcare
United States

AbbVie Inc. (ABBV) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It carries out the research, development, manufacture and commercialization of advanced therapies to address complex and serious diseases. The company’s products are used to treat Crohn’s disease, cystic fibrosis complications, HIV, low testosterone, Parkinson’s disease, rheumatoid arthritis, psoriasis, thyroid related issues, ulcerative colitis, complications associated with chronic kidney disease and others. AbbVie is also developing products across several other medical specialties such as cancer, renal care, immunology, hepatitis C virus, women’s health and neuroscience, including Alzheimer’s disease and multiple sclerosis. The company operates through subsidiaries in North America, South America, Asia, Europe, Middle East and South Africa. AbbVie is headquartered in North Chicago, Illinois, the US.

AbbVie Inc. Key Recent Developments

Feb 19, 2015: Abbvie Increases Quarterly Dividend
Jan 30, 2015: Abbvie Reports Fourth-Quarter And Full-Year 2014 Financial Results
Jan 20, 2015: Abbvie Innovation Center Opens At Research Park
Jan 12, 2015: Prime Therapeutics Breaks from Competition, Strikes Deals to Prefer both Harvoni, Viekira Hepatitis C Drugs
Dec 26, 2013: Foundation for the NIH Announces First Results of I-SPY 2 Breast Cancer Clinical Trial

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
AbbVie Inc. – Key Facts 6
AbbVie Inc. – Key Employees 7
AbbVie Inc. – Key Employee Biographies 8
AbbVie Inc. – Major Products and Services 9
AbbVie Inc. – Pharmaceutical Pipeline Products Data 11
AbbVie Inc., Pipeline Products by Therapy Area 11
AbbVie Inc., Pipeline Products by Development Phase 12
AbbVie Inc. – History 18
AbbVie Inc. – Company Statement 22
AbbVie Inc. – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Section 2 – Company Analysis 32
AbbVie Inc. – Business Description 32
AbbVie Inc. – SWOT Analysis 34
SWOT Analysis – Overview 34
AbbVie Inc. – Strengths 34
Strength – Lead Product – Humira 34
Strength – Leading Market Position 34
Strength – Research and Development Activities 34
AbbVie Inc. – Weaknesses 35
Weakness – Decline in Top Products Sales 35
Weakness – Clinical Results 35
Weakness – Declining Bottom-line 35
AbbVie Inc. – Opportunities 36
Opportunity – Orphan Drug Designation 36
Opportunity – Product Pipeline 36
Opportunity – Business Initiatives 36
AbbVie Inc. – Threats 37
Threat – Competitive Landscape 37
Threat – Dependence on Wholesale Distributors 37
Threat – Product Liability Claims 37
AbbVie Inc. – Key Competitors 38
Section 3 – Company Financial Ratios 39
Financial Ratios – Capital Market Ratios 39
Financial Ratios – Annual Ratios 40
Performance Chart 42
Financial Performance 42
Financial Ratios – Interim Ratios 43
Financial Ratios – Ratio Charts 44
Section 4 – Company’s Lifesciences Financial Deals and Alliances 45
AbbVie Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 45
AbbVie Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 46
AbbVie Inc., Recent Deals Summary 47
Section 5 – Company’s Recent Developments 48
Feb 19, 2015: Abbvie Increases Quarterly Dividend 48
Jan 30, 2015: Abbvie Reports Fourth-Quarter And Full-Year 2014 Financial Results 49
Jan 20, 2015: Abbvie Innovation Center Opens At Research Park 51
Jan 12, 2015: Prime Therapeutics Breaks from Competition, Strikes Deals to Prefer both Harvoni, Viekira Hepatitis C Drugs 52
Oct 31, 2014: AbbVie Reports Third-Quarter 2014 Financial Results 53
Oct 20, 2014: AbbVie Announces New $5 Billion Stock Repurchase Program and Increases Dividend 55
Sep 19, 2014: AbbVie Declares Quarterly Dividend 56
Sep 03, 2014: AbbVie And Calico Announce A Novel Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies 57
Aug 01, 2014: AbbVie and Cystic Fibrosis Research Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 58
Jul 25, 2014: AbbVie Reports Second-Quarter 2014 Financial Results 59
Section 6 – Appendix 60
Methodology 60
Ratio Definitions 60
About GlobalData 64
Contact Us 64
Disclaimer 64



List of Tables
AbbVie Inc., Key Facts 6
AbbVie Inc., Key Employees 7
AbbVie Inc., Key Employee Biographies 8
AbbVie Inc., Major Products and Services 9
AbbVie Inc., Number of Pipeline Products by Therapy Area 11
AbbVie Inc., Number of Pipeline Products by Development Stage 12
AbbVie Inc., Pipeline Products By Therapy Area and Development Phase 13
AbbVie Inc., History 18
AbbVie Inc., Subsidiaries 24
AbbVie Inc., Key Competitors 38
AbbVie Inc., Ratios based on current share price 39
AbbVie Inc., Annual Ratios 40
AbbVie Inc., Interim Ratios 43
AbbVie Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 45
AbbVie Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 46
AbbVie Inc., Recent Deals Summary 47
Currency Codes 60
Capital Market Ratios 60
Equity Ratios 61
Profitability Ratios 61
Cost Ratios 62
Liquidity Ratios 62
Leverage Ratios 63
Efficiency Ratios 63



List of Figures
AbbVie Inc., Pipeline Products by Therapy Area 11
AbbVie Inc., Pipeline Products by Development Phase 12
AbbVie Inc., Performance Chart (2010 – 2014) 42
AbbVie Inc., Ratio Charts 44
AbbVie Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 45
AbbVie Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 46

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $300

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.